Shamita Shah, MD
Gastroenterology · New Orleans, LANPI 1740302710
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,185 of the $114,140 with a category attached, or 79.0%. 9 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 38.8% of the total. Reporting peaked in 2019 at $31,622 and has fallen 74.7% since, to $8,000 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $1108.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$44K
- Pfizer$24K
- E.r. Squibb & Sons, L.L.C.$16K
- AbbVie$16K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Bristol Myers Squibb$883
- plus $223 from 3 others
Across 10 payments — averaging $36,533 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Scientific Affairs, LLC$365K
What the payments were for
- Consulting fees$16,60015%
- Speaking & faculty fees$90,18579%
- Travel & lodging$3,7113%
- Food & beverage$3,5703%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 32 | $44,269 |
| Pfizer | 18 | $24,119 |
| E.r. Squibb & Sons, L.L.C. | 10 | $16,246 |
| AbbVie | 22 | $16,146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $12,254 |
| Bristol Myers Squibb | 6 | $883 |
| Gilead | 1 | $124 |
| ERBE USA Inc | 1 | $80 |
| Sandoz | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,140 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 48 | $1,214,301 |
| Humira(Cf) PenAdalimumab | 57 | $759,428 |
| RinvoqUpadacitinib | 33 | $271,973 |
| EntyvioVedolizumab | 13 | $117,393 |
| Mesalamine | 51 | $25,580 |
| Mesalamine DrMesalamine | 11 | $7,448 |
| Balsalazide Disodium | 27 | $5,530 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,541 |
| Mesalamine ErMesalamine | 16 | $2,413 |
| Azathioprine | 70 | $1,877 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 24 | $1,711 |
| Lubiprostone | 12 | $652 |
| Ondansetron OdtOndansetron | 25 | $556 |
| LoperamideLoperamide Hcl | 14 | $488 |
| Dicyclomine Hcl | 11 | $371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $16,146 | $271,97333 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $12,254 | $117,39313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in New Orleans
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Vivek HuilgolNew Orleans$37K
- Arnab RayNew Orleans$26K
- Janak ShahNew Orleans$18K
- Stephen LandreneauNew Orleans$17K
- Virendra JoshiNew Orleans$16K
- Parth ParekhNew Orleans$10K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.